{
    "clinical_study": {
        "@rank": "51942", 
        "arm_group": {
            "arm_group_label": "Treatment (SBRT, nephrectomy)", 
            "arm_group_type": "Experimental", 
            "description": "Patients undergo SBRT on day 1 and undergo partial or radical nephrectomy on day 29."
        }, 
        "brief_summary": {
            "textblock": "This pilot clinical trial studies stereotactic body radiation therapy in treating patients\n      with metastatic kidney cancer undergoing surgery. Stereotactic radiation therapy may be able\n      to send x-rays directly to the tumor and cause less damage to normal tissue."
        }, 
        "brief_title": "Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery", 
        "condition": [
            "Recurrent Renal Cell Cancer", 
            "Stage IV Renal Cell Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Carcinoma, Renal Cell"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Assess the impact of stereotactic body radiation therapy (SBRT) on the immune system in\n      patients with metastatic renal cell carcinoma (RCC).\n\n      SECONDARY OBJECTIVES:\n\n      I. Assess changes in immune parameters prior to radiation, post radiation and post\n      nephrectomy.\n\n      TERTIARY OBJECTIVES:\n\n      I. Assess surgical parameters for partial or radical nephrectomy post SBRT.\n\n      OUTLINE:\n\n      Patients undergo SBRT on day 1 and undergo partial or radical nephrectomy on day 29.\n\n      After completion of study treatment, patients are followed up at 30 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have metastatic RCC with primary tumor in place\n\n          -  Must be surgical candidates as deemed fit by surgeon\n\n          -  Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\n             criteria present\n\n          -  Patients of child-bearing potential must agree to use adequate contraceptive methods\n             (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry\n             and for the duration of study participation; should a woman become pregnant or\n             suspect she is pregnant while she or her partner is participating in this study, she\n             should inform her treating physician immediately\n\n          -  Patient or legal representative must understand the investigational nature of this\n             study and sign an Independent Ethics Committee/Institutional Review Board approved\n             written informed consent form prior to receiving any study related procedure\n\n        Exclusion Criteria:\n\n          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for\n             nitrosoureas or mitomycin C) prior to entering the study or those who have not\n             recovered from adverse events due to agents administered more than 4 weeks earlier\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements\n\n          -  Radiation to primary tumor prior to enrollment in this study\n\n          -  Pregnant or nursing female patients\n\n          -  Unwilling or unable to follow protocol requirements\n\n          -  Any condition which in the Investigator's opinion deems the patient an unsuitable\n             candidate to receive treatment\n\n          -  Received an investigational agent within 30 days prior to enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01892930", 
            "org_study_id": "I 212712", 
            "secondary_id": [
                "NCI-2013-01201", 
                "P30CA016056"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (SBRT, nephrectomy)", 
                "description": "Undergo SBRT", 
                "intervention_name": "stereotactic body radiation therapy", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "SBRT", 
                    "stereotactic radiation therapy", 
                    "stereotactic radiotherapy"
                ]
            }, 
            {
                "arm_group_label": "Treatment (SBRT, nephrectomy)", 
                "description": "Undergo partial or radical nephrectomy", 
                "intervention_name": "therapeutic conventional surgery", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Treatment (SBRT, nephrectomy)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 4, 2014", 
        "location": {
            "contact": {
                "email": "ASKRPCI@roswellpark.org", 
                "last_name": "Roswell Park", 
                "phone": "877-275-7724"
            }, 
            "facility": {
                "address": {
                    "city": "Buffalo", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14263"
                }, 
                "name": "Roswell Park Cancer Institute"
            }, 
            "investigator": {
                "last_name": "Thomas Schwaab", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Immunologic Impact of Stereotactic Body Radiation Therapy (SBRT) in Renal Cell Carcinoma", 
        "overall_official": {
            "affiliation": "Roswell Park Cancer Institute", 
            "last_name": "Thomas Schwaab", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Feasibility of conducting a partial nephrectomy in patients with no prior stereotactic radiation for kidney cancer", 
            "safety_issue": "No", 
            "time_frame": "Up to 30 days post-treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01892930"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Toxicity analysis assessed by the CTEP Version 4 of the NCI Common Terminology Criteria for Adverse Events (CTCAE)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 30 days post-treatment"
        }, 
        "source": "Roswell Park Cancer Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Roswell Park Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}